
NASA Spacecraft ‘Touches Sun' For Final Time In Defining Moment For Humankind
The heavily armored Parker Solar Probe has traveled to within just 3.86 million miles (6.1 million kilometers) of the sun's surface — what NASA calls 'hyper close.' It's the third and final time it has performed the feat, following similar achievements on Dec. 24, 2024, and March 22, 2025.
Parker launched on Aug. 12, 2018, and has since conducted 23 perihelions — close passes — of the sun, getting to within 3.86 million miles (6.1 million kilometers) twice before today's repeat performnce.
For scale, that's four yards from the end zone if the distance between Earth and the sun was the length of an American football field, according to mission scientists.
During this final perihelion of the mission, the probe will be traveling at around 430,000 miles per hour (690,000 kilometers per hour). According to NASA, that's fast enough to get from Philadelphia to Washington, D.C., in a single second.
Perihelion 24 also sees it forced to withstand temperatures of 1,600 to 1,700 degrees Fahrenheit (870 to 930 degrees Celsius). Its only armor against both temperature and extreme ultraviolet radiation is a carbon composite shield.
Parker is in a highly elliptical orbit, which takes 88 days but allows it to occasionally swoop particularly close to the sun.
One of the main objectives of the mission is to understand why the sun's corona, its outer atmosphere, is a million times hotter than the photosphere, its surface.
The corona is where the solar wind originates from, so solar physicists must understand it better if they are to forecast space weather more accurately. That's important because the state of the solar wind — a stream of charged particles interacting with the Earth's atmosphere — can damage satellites and harm astronauts, as well as cause Northern Lights.
The latter half of Parker's mission has coincided with the peak of Solar Cycle 25, the current 11-year-long cycle of the sun, during which our star experiences a waxing and waning of magnetic activity.
A study published on June 3 used data from Parker while flying close to the sun, reveal a new source for energetic particles in the solar corona. The mechanism, called magnetic reconnection, heats the solar atmosphere, accelerating solar wind particles. Magnetic reconnection — when magnetic field lines converge, break apart and reconnect in an explosive physical process — is responsible for powerful solar events, such as solar flares and coronal mass ejections.
'We've seen how magnetic reconnection behaves near Earth, but Parker has now shown how potent it is near the sun, where magnetic fields are significantly stronger,' said Dr. Mihir Desai, lead author and a scientist at the Southwest Research Institute in San Antonio, Texas.
Parker isn't going anywhere. Locked in the orbit of the sun, it will continue to loop around our star. However, it was gravity assists at Venus that gave the spacecraft enough momentum to get so close to the sun. No, it's within the orbit of Venus, that opportunity is lost, so it won't be able to reach any closer to the sun than it already has done.
According to Live Science, the spacecraft's thrusters will eventually run out of fuel, and it will burn up, though its heat shield may remain in orbit for thousands of years.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
Indivior Presents New Data at CPDD Demonstrating that High Buprenorphine Exposure May Improve Treatment Outcomes in High Fentanyl Users
A post-hoc analysis demonstrates that buprenorphine exposure with 300 mg SUBLOCADE® (buprenorphine extended-release) may improve treatment outcomes among opioid use disorder (OUD) patients with heavy fentanyl use1 Additional Indivior-funded research identified OUD treatment barriers in American Indian/Alaska Native (AI/AN) people who are often affected by higher drug overdose death rates compared to other racial and ethnic groups2-5 RICHMOND, Va., June 19, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq: INDV) presented new findings this week at the College on Problems of Drug Dependence (CPDD) Annual Scientific Meeting. A post hoc analysis showed that patients with heavier fentanyl use experienced clinically meaningful improvements in opioid abstinence when treated with a 300 mg maintenance dose of SUBLOCADE, compared to the 100 mg dose. While the 300 mg dose did not demonstrate a statistically significant advantage over 100 mg for weekly abstinence—the study's primary endpoint—in the overall population with moderate to severe opioid use disorder (OUD), the results suggest that higher doses of SUBLOCADE may offer better outcomes for individuals with high levels of fentanyl use. "These findings offer additional evidence that the higher maintenance dose of SUBLOCADE is safe and may better support patients with intense fentanyl use patterns," said Christian Heidbreder, Ph.D., Chief Scientific Officer at Indivior. "We aim to provide clinicians with new data that can transform treatment strategies and support patients on their journey to recovery." In the Indivior-funded study, patients with OUD who engaged in high-risk opioid use—such as injection use, high opioid dose consumption, or fentanyl use—received two initial 300 mg injections of SUBLOCADE one week apart. They were then randomized to receive eight monthly maintenance doses of either 100 mg or 300 mg. Both dosing regimens led to significant reductions in opioid use: the average weekly use dropped sharply from over 40 instances at screening to fewer than 3 by Week 3, and this improvement was sustained through Week 38. Notably, no new safety concerns were identified with either the 100 mg or 300 mg maintenance doses. Indivior also funded research exploring OUD treatment access and outcomes in American Indian/Alaska Native (AI/AN) populations, which were presented at CPDD. AI/AN populations experience disproportionate rates of OUD, drug overdose, and gap in access to OUD care. A thematic analysis of focus group research on nine AI/AN advocates indicated that AI/AN people experience significant barriers to accessing medication for opioid use disorder (MOUD).4-8 Barriers include stigma, institutional challenges, and transitions of care for OUD, highlighting opportunities for culturally appropriate interactive education and institutional advancement.2 These focus group findings are illustrative and can be used to identify avenues for future work, although they may not be generalizable to the full population. In addition, a large multi-year longitudinal claims database analysis of more than 75,000 AI/AN patients with evidence of OUD showed differences in utilization of MOUD among those seeing Indian Health Services (IHS) vs. non-IHS providers. The majority of patients (73.1%) saw non-IHS providers. Patients treated with any form of MOUD had lower all-cause emergency department vs. those who were not treated with MOUD, highlighting the need for further research to understand MOUD utilization among AI/AN. "The collective evidence from these presentations highlights prominent barriers to effective care and helps map out appropriate treatment approaches for individuals with OUD in challenging treatment settings," said Heidbreder. "Indivior focuses its scientific, treatment, and policy efforts on helping patients access the medications and support they need to recover." Key Abstracts Presented at CPDD: Higher Exposures with 300-Mg Buprenorphine Extended-Release (BUP-XR) Increased the Proportion of Responders Among Opioid Use Disorder (OUD) Patients with Heavy Fentanyl Use Barriers to and Facilitators of Medication Treatment for Opioid Use Disorder Identified by American Indian/Alaska Native Advocates Utilization of Medications for Opioid Use Disorder (MOUD) and Patient Profiles Amongst American Indian/Alaska Native Managing Opioid Use Disorder (OUD) Polysubstance Use in Treatment for Opioid Use Disorder: Opioid Abstinence and Alternative Substance Use Clinical Outcomes and Recovery in Adults with Opioid Use Disorder: Long-term Treatment with Long- acting Injectable Buprenorphine under Real-World Conditions Severity and Symptomatology of Opioid Use Disorder (OUD) Among Individuals Reporting Pain Reliever Use, Pain Reliever Misuse, and/or Heroin Use: A Cross-sectional Analysis of the 2021 and 2022 National Survey on Drug Use and Health Disclosure: This press release has been issued by Indivior Inc. and the content has not been approved or authorized by the College on Problems of Drug Dependence. About SUBLOCADE® SUBLOCADE® (buprenorphine extended-release) injection, for subcutaneous use, CIII INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. SUBLOCADE should be used as part of a complete treatment plan that includes counseling and psychosocial support. HIGHLIGHTED SAFETY INFORMATION WARNING: RISK OF SERIOUS HARM OR DEATH WITH INTRAVENOUS ADMINISTRATION; SUBLOCADE RISK EVALUATION AND MITIGATION STRATEGY Serious harm or death could result if administered intravenously. SUBLOCADE forms a solid mass upon contact with body fluids and may cause occlusion, local tissue damage, and thrombo-embolic events, including life-threatening pulmonary emboli, if administered intravenously. Because of the risk of serious harm or death that could result from intravenous self-administration, SUBLOCADE is only available through a restricted program call the SUBLOCADE REMS Program. Healthcare settings and pharmacies that order and dispense SUBLOCADE must be certified in this program and comply with the REMS requirements. CONTRAINDICATIONS Hypersensitivity to buprenorphine or any other ingredients in SUBLOCADE. WARNINGS AND PRECAUTIONS Addiction, Abuse, and Misuse: SUBLOCADE contains buprenorphine, a Schedule III controlled substance that can be abused in a manner similar to other opioids. Monitor patients for conditions indicative of diversion or progression of opioid dependence and addictive behaviors. Respiratory Depression: Life threatening respiratory depression and death have occurred in association with buprenorphine. Warn patients of the potential danger of self-administration of benzodiazepines or other CNS depressants while under treatment with SUBLOCADE. Risk of Serious Injection Site Reactions: Likelihood of may increase with inadvertent intramuscular or intradermal administration. Evaluate and treat as appropriate. The most common injection site reactions are pain, erythema and pruritus with some involving abscess, ulceration and necrosis. Neonatal Opioid Withdrawal Syndrome: Neonatal opioid withdrawal syndrome (NOWS) is an expected and treatable outcome of prolonged use of opioids during pregnancy. Adrenal Insufficiency: If diagnosed, treat with physiologic replacement of corticosteroids, and wean patient off of the opioid. Risk of Opioid Withdrawal with Abrupt Discontinuation: If treatment with SUBLOCADE is discontinued, monitor patients for several months for withdrawal and treat appropriately. Risk of Hepatitis, Hepatic Events: Monitor liver function tests prior to and during treatment. Risk of Withdrawal in Patients Dependent on Full Agonist Opioids: Verify that patients have tolerated transmucosal buprenorphine before injecting SUBLOCADE. Treatment of Emergent Acute Pain: Treat pain with a non-opioid analgesic whenever possible. If opioid therapy is required, monitor patients closely because higher doses may be required for analgesic effect. ADVERSE REACTIONS Adverse reactions commonly associated with SUBLOCADE (in ≥5% of subjects) were constipation, headache, nausea, injection site pruritus, vomiting, increased hepatic enzymes, fatigue, and injection site pain. For more information about SUBLOCADE, the full Prescribing information including BOXED WARNING, and Medication Guide, visit About Opioid Use Disorder (OUD) Opioid Use Disorder (OUD) is a chronic disease in which people develop a pattern of using opioids that can lead to negative consequences. OUD may affect the parts of the brain that are necessary for life-sustaining functions. About Indivior Indivior is a global pharmaceutical company working to help change patients' lives by developing medicines to treat opioid use disorder (OUD). Our vision is that all patients around the world will have access to evidence-based treatment for OUD and we are dedicated to transforming OUD from a global human crisis to a recognized and treated chronic disease. Building on its global portfolio of OUD treatments, Indivior has a pipeline of product candidates designed to expand on its heritage in this category. Headquartered in the United States in Richmond, VA, Indivior employs over 1,000 individuals globally and its portfolio of products is available in over 30 countries worldwide. Visit to learn more. Connect with Indivior on LinkedIn by visiting Higher Exposures with 300-Mg Buprenorphine Extended-Release (BUP-XR) Increased the Proportion of Responders Among Opioid Use Disorder (OUD) Patients with Heavy Fentanyl Use [Late Breaking Oral Sessions]. CPDD Annual Scientific Meeting, June 15, 2025. Barriers To and Facilitators Of Medication Treatment for Opioid Use Disorder Identified by American Indian/Alaska Native Advocates [Oral Session: Expanding SUD interventions across populations]. CPDD Annual Scientific Meeting, June 17, 2025. Utilization of Medications for Opioid Use Disorder (MOUD) and Patient Profiles amongst American Indian/Alaska Native Managing Opioid Use Disorder (OUD) [Poster Session 1]. CPDD Annual Scientific Meeting, June 15, 2025. Indian Health Service. Disparities. 2019. Retrieved from Accessed: 16 May 2024. Centers for Disease Control and Prevention, National Center for Health Statistics (2024). Rate of National Drug Overdose Deaths, By Demographic. Available at: statistics/overdose-death-rates. Accessed: 6 Jun 2024. Soto C, et al. (2022). International Journal of Environmental Research and Public Health, 19(5), 2974. doi:10.3390/ijerph19052974 Krawczyk N, et al. . Drug Alcohol Depend. 2021 Mar 1;220:108512. doi: 10.1016/ Mpofu, E, et al.. (2021). Addictive Behaviors, 114, 106743. doi:10.1016/ View original content to download multimedia: SOURCE Indivior PLC Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
Satsuma Pharmaceuticals and SNBL Announce Four Abstracts to be Presented at the American Headache Society's 67th Annual Scientific Meeting
DURHAM, N.C., June 19, 2025 /PRNewswire/ -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company dedicated to bringing novel treatments to people who suffer from migraine and other debilitating conditions, and its corporate parent, Shin Nippon Biomedical Laboratories, Ltd. (TSE:2395), today announced that four abstracts describing efficacy and safety results from Satsuma's Phase 3 clinical study program were selected for presentation at the American Headache Society's (AHS) 67th Annual Scientific Meeting. The 2025 meeting will be held at the Minneapolis Convention Center Minneapolis, MN, from Thursday, June 19 to Sunday, June 22, 2025, including the option of participants attending virtually. Full abstracts are now available on the AHS website and will be published in the journal Headache®. Poster Presentation Details: Title: DHE Plasma Concentration and Clinical Response Relationship – An In-Office PK-PD Study Presenter: Detlef Albrecht, MD Poster: P-305 Date: Friday, June 20, 2025 Time: 5:00 PM – 6:15 PM CT (6:00 PM – 7:15 PM ET) Title: Strong CYP3A4 Inhibitor Itraconazole Does Not Cause Clinically Relevant Interactions with STS101 (Nasal Dihydroergotamine Powder) Presenter: Detlef Albrecht, MD Poster: P-307 Date: Friday, June 20, 2025 Time: 5:00 PM – 6:15 PM CT (6:00 PM – 7:15 PM ET) Title: STS101 Use Reduces Migraine Frequency Over Time Presenter: Stewart Tepper, MD Poster: P-309 Date: Friday, June 20, 2025 Time: 5:00 PM – 6:15 PM CT (6:00 PM – 7:15 PM ET) Title: STS101 (Dihydroergotamine Nasal Powder) Shows Benefit on the Resolution of Cardinal Migraine Symptoms Photophobia, Phonophobia, and Nausea: Results from the Long-Term Phase 3 Open-Label ASCEND Study Presenter: Amaal J. Starling, MD Poster: P-310 Date: Thursday, June 19, 2025 Time: 6:00 PM – 7:30 PM CT (7:00 PM – 8:30 PM ET) About Satsuma and STS101 Satsuma Pharmaceuticals, a wholly owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), is a late-stage biopharmaceutical company that recently received regulatory approval from the U.S. Food and Drug Administration for STS101, with the approved name Atzumi™ (Dihydroergotamine) nasal powder. For more information, please visit Satsuma is headquartered in Research Triangle Park, North Carolina. About SNBL Shin Nippon Biomedical Laboratories, Ltd. ("SNBL") (TSE:2395) is a listed nonclinical contract research organization (CRO) that was founded in Kagoshima, Japan, in 1957. Based on its corporate philosophy of "Committed to the environment, life, and people", and with a proven track record of accomplishment as the oldest and most established Japanese nonclinical CRO, SNBL is proud to offer a comprehensive portfolio of services and solutions for drug discovery and development for pharmaceutical companies, biotech ventures, universities, and research institutions both in Japan and overseas. The SNBL's Translational Research business engages in drug discovery, with the focus on business development and out-licensing of its proprietary intranasal drug delivery technologies and intranasal devices. For further information, please visit Cautionary Note on Forward-Looking Statements Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding SNBL's future business, future position and results of operations, including estimates, forecasts, targets and plans for SNBL. Without limitation, forward-looking statements often include words such as "targets", "plans", "believes", "hopes", "continues", "expects", "aims", "intends", "ensures", "will", "may", "should", "would", "could" "anticipates", "estimates", "projects" or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding SNBL's business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of product candidates; the impact of health crises such as the coronavirus pandemic on SNBL and its clients and suppliers, including foreign governments in countries in which SNBL operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to SNBL's operations and the timing of any such divestment(s); and other factors identified in SNBL's most recent securities report ("YukaShoken Houkokusho") and SNBL's other reports filed with the Financial Services Agency, available on SNBL's website at: or at SNBL does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or related stock exchange rule. Past performance is not an indicator of future results and the results or statements of SNBL in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of SNBL's future results. Medical information This press release contains information about product candidates that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Inquiries:Satsuma Pharmaceuticals, Inc.E-mail: info@ View original content to download multimedia: SOURCE Satsuma Pharmaceuticals, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Newsweek
26 minutes ago
- Newsweek
Mexican Sewage Flooding Into California Can Be Seen From Space
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A NASA instrument aboard the International Space Station has detected contamination from Mexican sewage that spilled into the Pacific Ocean off the coast of Southern California. Why It Matters The Tijuana River flows from Mexico into California and drains into the Pacific Ocean, transporting millions of gallons of untreated sewage along with it. This long-standing issue has raised alarms over its impact on both public health and the environment. What To Know The instrument, known as the Earth Surface Mineral Dust Source Investigation (EMIT), was originally used to map minerals in desert regions but is now offering insights into water quality. In a recent study, EMIT was able to identify phycocyanin—a pigment found in cyanobacteria—within a massive wastewater plume off the mouth of the Tijuana River. A plume spreads out to sea in this image captured off San Diego by the Sentinel-2 satellite on March 24, 2023. A plume spreads out to sea in this image captured off San Diego by the Sentinel-2 satellite on March 24, 2023. SDSU/Eva Scrivner/NASA Cyanobacteria are an organism capable of causing illness in humans and animals through ingestion or inhalation, NASA said. EMIT operates by analyzing light reflected from Earth's surface, breaking it down into hundreds of visible and infrared color bands. Each material, including pollutants, has a unique spectral signature that allows scientists to identify it. Researchers matched EMIT's satellite data of the Tijuana River plume with results from ground-tested water samples. Both methods identified a spectral signature indicating the presence of phycocyanin. The findings come as Southern California beaches near the United States-Mexico border have repeatedly faced closures due to contamination. Millions of gallons of wastewater enter the Tijuana River annually, emptying into the ocean and posing a health hazard to swimmers and military personnel stationed in the area. San Diego County beaches have seen 1,000 days' worth of closures in recent years, and a report from the Department of Defense's Office of Inspector General documented 1,100 cases of illness among Navy SEALs and other service members exposed to polluted waters. What People Are Saying Christine Lee, a scientist at NASA's Jet Propulsion Laboratory and a co-author of the study, said: "From orbit you are able to look down and see that a wastewater plume is extending into places you haven't sampled. "It's like a diagnostic at the doctor's office that tells you, 'Hey, let's take a closer look at this.'" Eva Scrivner, a doctoral student at the University of Connecticut and the study's lead author, said that the findings "show a 'smoking gun' of sorts for wastewater in the Tijuana River plume." What Happens Next Lee Zeldin, the administrator of the Environmental Protection Agency, stated in May that the U.S. International Boundary and Water Commission was expediting an expansion of the South Bay International Wastewater Treatment Plant, which treats sewage and wastewater from Tijuana, by 10 million gallons per day in an effort to mitigate the crisis.